New Study Demonstrates NanoScan Imaging's Novel Contrast Agent May Identify Heart Attack in Waiting
Published: Jun 11, 2009
LANSDALE, Pa.--(BUSINESS WIRE)--NanoScan Imaging, LLC today announced the publication of new data demonstrating the use of its investigational, radio-opaque contrast agent (N1177) to visualize vulnerable plaques that can cause heart attack or stroke using advanced, non-invasive and high-resolution computed tomography (CT) techniques. Results of the study were published in the current issue of the peer-reviewed Journal of Nuclear Medicine (J Nucl Med. 2009 Jun;50(6):959-965).